Sanofi has high hopes for a pre-clinical therapy it believes can fight liver cancer in China. In an interview with Reuters in Hong Kong, Sanofi CEO Chris Viehbacher (photo) said that investigators would push ahead with the first human studies of the therapy, called slit-trap, next year. Sanofi ($SNY) is one of a number of biopharma outfits that has big expectations for the Chinese drug market in years to come, with a large budget for burgeoning research operations in Asia. Liver cancer, which is rife in China and rare in the West, makes a good initial target for them to go after. Story